News & Updates

Show Multimedia Only

Indapamide prevents death, cardiac events in at-risk patients

31 Mar 2023 by

Long-term treatment with indapamide with or without perindopril-based therapy results in a significant reduction in the risk of all-cause mortality, cardiovascular death, fatal stroke, and total stroke among patients with medium to high cardiovascular risk, according to a pooled analysis of four trials.

Indapamide prevents death, cardiac events in at-risk patients

31 Mar 2023

Rituximab, cyclophosphamide deliver similar effects on ENT symptoms in AAV

31 Mar 2023

Cyclophosphamide (CYC) and rituximab (RTX) show comparable therapeutic effects on ear, nose, and throat (ENT) symptoms in patients with antineutrophil cytoplasmic antibody–associated vasculitis (AAV).

Rituximab, cyclophosphamide deliver similar effects on ENT symptoms in AAV

31 Mar 2023

Novel device delivers improvements for BPH symptoms

31 Mar 2023 by

The Optilume™ BPH Catheter System, a novel minimally invasive surgical therapy (MIST), provided rapid improvements for men with benign prostatic hyperplasia (BPH), the PINNACLE trial reports.

Novel device delivers improvements for BPH symptoms

31 Mar 2023

Antibiotics linked to higher EAC risk

31 Mar 2023

Exposure to any antibiotics appears to contribute to an increase in the risk of esophageal adenocarcinoma (EAC), with the risk rising as the cumulative days of exposure increases, according to a study.

Antibiotics linked to higher EAC risk

31 Mar 2023

Original New Drug Application Approvals by US FDA (16-31 March 2023)

31 Mar 2023

New drug applications approved by US FDA as of 16-31 March 2023 which includes New Molecular Entities (NMEs) and new biologics. It does not include Tentative Approvals. Supplemental approvals may have occurred since the original approval date.

Original New Drug Application Approvals by US FDA (16-31 March 2023)

31 Mar 2023

Tenofovir disoproxil fumarate as good as entecavir for patients with HBV-related liver cancer

30 Mar 2023

Treatment with tenofovir disoproxil fumarate (TDF) yields similar rates of recurrence and overall survival as does entecavir in patients with hepatitis B virus (HBV)-related hepatocellular carcinoma (HCC), according to a study.